Kevin McCulloch - 01 Sep 2026 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Reporting relationship: President and Chief Operating Officer
Issuer ticker: XERS
Reported as of: 01 Sep 2026
Net transaction value: -$127,308
SEC form: 4
Accepted by SEC: 01 Sep 2026, 18:21:17 UTC
Prior SEC filing: 04 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Beth Hecht, Attorney-in-Fact

Key filing fact

Kevin McCulloch filed Form 4 for Xeris Biopharma Holdings, Inc. (XERS) on 01 Sep 2026.

Key facts

This page summarizes Kevin McCulloch's Form 4 filing for Xeris Biopharma Holdings, Inc. (XERS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 01 Sep 2026, 18:21.

Change

Previous filing in this sequence was filed on 04 Aug 2026.
Current net transaction value: -$127,308.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002031695 Primary reporting owner

McCulloch Kevin

Relationship: President and Chief Operating Officer
Address: C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO
Signature: /s/ Beth Hecht, Attorney-in-Fact
Signature date: 01 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XERS transaction

Common Stock

Sale

Transaction value: $127,308
Shares: -15,000
Change %: -0.91%
Price: $8.49
Shares after: 1,639,208
Date: 01 Sep 2026
Ownership: Direct
Footnotes: F1, F2

XERS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 25,000
Date: 01 Sep 2026
Ownership: By Spouse
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

The transaction was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on September 4, 2025.

Footnote F2

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.390 to $8.600, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F3

The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC remarks

President and Chief Operating Officer